SYNTHESIS AND IN VITRO ANTICANCER ACTIVITY OF 8-CHLORO-3-CYANO-4-IMINO-2-METHYLTHIO-4H-PYRIMIDO [2, 1-B] [1, 3] BENZOTHIAZOLE AND ITS 2-SUBSTITUTED DERIVATIVES by SHARAD VK, LEENA BL, GIRIDHAR RS
JPRHC 
Research Article 
 
 
JPRHC                         Volume 2                                 Issue 3                                         273-278 
SYNTHESIS AND IN VITRO ANTICANCER ACTIVITY OF 8-CHLORO-3-CYANO-4-IMINO-2-METHYLTHIO-4H-
PYRIMIDO [2, 1-B] [1, 3] BENZOTHIAZOLE AND ITS 2-SUBSTITUTED DERIVATIVES 
 
DR. LEENA B. LABHSETWAR, DR. GIRIDHAR R. SHENDARKAR, DR. SHARAD V. KUBERKAR  
For author affiliations, see end of text 
This paper is available online at www.jprhc.in 
 
 
 
 ABSTRACT:- 
 
                 8-Chloro-3-cyano-4-imino-2-methylthio-4H-
pyrimido [2, 1-b] [1, 3] benzothiazole and its 2-substituted 
derivatives has been prepared and evaluated at National 
Cancer Institute, Maryland, USA for their in vitro anticancer 
activity towards 60 Human Cancer cell lines, derived from 
various cancer types. Results revealed that all these 
compounds displayed remarkable anticancer action across 
human cancer cell lines. Compounds 3, 4c and 4e are selected 
by NCI for further anticancer activity at five dose 
concentration level.  
Keywords: Benzothiazole, Human cancer cell lines, Anti 
canceraction.
 
  
 
 
INTRODUCTION:-- 
 
            Pyrimidine, iminopyrimidine 1-5 and fused 
benzothiazole heterocycles 5-6 are reported to be effective 
pharmacophores. Domino et.al. 7 reported the use of 2-
benzothiazolamines as central muscle relaxant. Jimonet and 
his research group 8 reported synthesis and pharmacological 
activity of 3- substituted-2-imino benzothiazolines which 
were found to be three times more potent than Riluzole, a 
blocker of excitatory amino acid mediated neurotransmission. 
It has been found that small and simple heterocyclic structures 
surprisingly exhibit complex pharmaceutical properties. M. 
F.G. Stevens et.al. 9-12 reported that benzothiazoles display 
antitumor properties that are modulated by substitutents at 
specific positions on the benzothiazole pharmacophore. 2-(4-
Amino -3-methyl phenyl)  benzothiazole (DF203) and 2-(4-
amino phenyl) benzothiazole represent the lead compounds 
for a recently explored series and possess potent antitumor 
properties in select breast, ovarian and renal cancer cell lines 
of the 60 -cell line. E. Brantlsy et.al. 13 reported that 
fluorinated 2-(4-amino-3-methyl phenyl) benzothiazole, 
induced to CYPIA1 expression, become metabolized and bind 
to macromolecules in sensitive Human Cancer cells. 
Recently, Suvarna Kini and her research group 14 synthesized 
novel benzothiazole derivatives and evaluated against Human 
Cervical Cancer cell lines.                
            Biological activities and various applications of 
pyrimidines, iminopyrimidines, amino and imino 
benzothiazoles, have stimulated our interest to explore the 
synthesis of new potential compounds in which pyrimidine / 
imino pyrimidine pharmacophores are fused with another 
pharmacophore such as benzothiazole through nitrogen atom. 
Hence we thought it worthwhile to design and synthesize 
fused pyrimido benzothiazoles, such as 8-Chloro-3-cyano-4-
imino-2-methylthio-4H-pyrimido[2,1-b][1,3] benzothiazole 
and its 2- substituted derivatives and to evaluate at National 
Cancer Institute, Maryland, USA15 for their in vitro anticancer 
activity towards 60 human cancer cell lines derived from 
cancer types like Non-small cell Lung cancer, Colon cancer, 
Breast cancer, Ovarian cancer, Leukemia, Renal cancer,  
Melanoma , Prostate cancer and CNS cancer. 
 
EXPERIMENTAL PROCEDURE: 
 General 
 Melting points (uncorrected) were determined in open 
capillary tubes. The purity of compounds was checked by 
TLC using silica gel .The IR spectra in KBr were recorded on 
a FTIR-8400S (Shimadzu). The 1H NMR spectra in CDCl3 
and 13C NMR spectra in DMSO were recorded on a Gemini 
200 MHz spectrometer using TMS as an internal standard. 
Mass spectra were recorded on a FT VG 7070 H Mass 
spectrophotometer using EI technique 70 eV.  
 
 Syntheses 
 3: A mixture of 2-amino-6-chloro benzothiazole (10mmol), 
bis (methylthio) methylene malononitrile (10mmol) in N, N- 
dimethylformamide (15ml) and anhydrous potassium 
carbonate (10mg) was refluxed for 4-5 h. The mixture was 
allowed to stand overnight and poured in cold water. The 
separated crystalline solid was filtered off and washed with 
ice-cold water and recrystallized from N, N-
dimethylformamide-ethyl alcohol mixture to obtain 3, yield 
375 mg, (75%); M.p.: 230oC; IR: (FTIR): υ- = 3306,  2198; 
1H NMR [CDCl3]: δ= 2.7 (s, 3H, SCH3), 7.4-7.9 (m.3H, Ar-
H),9.5(s,1H,=NH);13C NMR: [DMSO] = (C1,CH3), 
115.04 (C2), 121.83(C5,Ar-C), 122.49(C6,Ar-C),  125.87(C3), 
127.39(C7,Ar-C), 130.86(C8,Ar-C), 135.40(C9,Ar-C), 
152.56(C10,Ar-C), 157(C4, C=N), 165 (C11,C=N) 168 (C12, 
CN) ;  Mass: Ms (70eV): m/z (%) = 308(30) [M+2] 306 
(90)[M+], 259 (80), 232 (20), 206 (10). Found (%):C, 52.40; 
H, 2.5; N, 20.20. Calc.for C12 H7 N4 S2 Cl (%): C, 52.46; H, 
2.7; N, 20.39. 
4,5,6 and 7 : A mixture of  compound 3 (10mmol) 
independently with various aromatic amines, heteryl amines, 
substituted phenols and compounds containing an active 
methylene group (10mmol) in N,N- dimethylformamide 
(10ml) and anhydrous potassium carbonate (10mg) was 
refluxed for 4-6 h. As soon as reaction mixture was cooled to 
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room temperature and poured into ice cold water, the 
separated crystalline solid was filtered off and washed with 
ice cold water to obtain 4(a-f),5(a-d), 6(a-d), 7(a-d).                                                                                                                                  
 4a: yield 60%; M.p.: 220oC; IR (FTIR): υ- = 3320, 3190, and 
2190; 1H NMR [CDCl3]: δ= 4.5 (br, s, 1H-NH), 7.1-7.7 (m, 
8H, Ar-H), 9.3 (s, 1H, =NH); Found (%): C, 57.94; H, 2.80; 
N, 19.80.   Calc. for C17 H10 N5 S Cl (%): C, 58.04; H, 2.87; 
N, 19.91.   
4b: yield 67%; M.p.: 180oC; IR (FTIR): υ- = 3300, 3170, 
2205, 1510, and 1360; 1H NMR [CDCl3]: δ= 4.2 (br, s, 1H,-
NH), 7.3-7.9 (m, 7 H, Ar-H), 9.1 (s, 1H, =NH); Found (%): C, 
51.30; H, 2.19; N, 21.08. Calc. for C17 H9 N6 SO2 Cl (%): C, 
51.40; H, 2.29; N, 21.18                 
4c: yield 70%; M.p.; 140oC; IR(FTIR): υ-= 3305, 3110, and 
2200;  1H NMR[CDCl3]: δ= 3.3 (s, 3H,-OCH3), 4.1(br, s, 1H,-
NH), 7.2-7.8 (m, 7H, Ar-H), 9.3 (s, 1H, =NH); Found (%): C, 
56.52;  H, 3.07; N,18.24. Calc.for C18 H12 N5 SO Cl (%) C, 
56.62; H, 3.17: N, 18.34  
4d:  yield 60%; M.p.: 170oC; IR (FTIR): υ-= 3305, 3111, 
2201; 1H NMR [CDCl3]: δ= 2.5 (s, 3H,-Ar-CH3), 4.6 (br, s, 
1H,-NH), 7.1-7.6 (m, 7H, Ar-H), 8. 9 (s, 1H, =NH); Found 
(%): C, 59.00; H,3.11; N,19.02.Calc.for C18 H12 N5 S Cl (%): 
C,59.10;H,3.31;N,19.14 . 
  4e:  yield 68%; M.p.: 190oC; IR (FTIR): υ-= 3320, 3180, 
2210. 1H NMR [CDCl3]: δ= 4.2(br, s, 1H,-NH), 7.2-7.8(m, 
7H, Ar-H), 9.4 (s, 1H, =NH). Found (%): C, 52.65; H, 2.11; 
N, 18.02. Calc.for C17 H9 N5 S Cl2 (%): C, 52.86; H, 2.35; N, 
18.13.    
 4f:  yield 68%; M.p.:192oC; IR (FTIR): υ-=3423, 3190, 2212; 
1H NMR [CDCl3]: δ= 1.5 (t, 6H,-2CH3), 2.9 (q, 4H,-2CH2), 
7.1-7.5 (m, 3H, Ar-H), 8.5 (s, 1H, =NH). Found (%): C, 
54.35; H, 4.21; N, 21.07.Calc.for C15H14N5 S Cl (%): C, 
54.36; H, 4.25, N, 21.11. 
5a:  yield 65%; M.p.: 180oC; IR (FTIR): υ-= 3423, 3190, 
2212;   1H NMR [CDCl3]: δ= 2.5 (t, 4 H, -NCH2), 3.5 (t, 4 H, 
-OCH2), 7.2-7.6 (m, 3H, Ar-H), 9.3 (s, 1H, =NH); Found (%): 
C, 51.96; H, 3.20; N, 20.20.  Calc. for C15H12N5OSCl (%): C, 
52.10; H, 3.50; N, 20.25.    
5b:  yield 69%; M.p.: 125oC; IR(FTIR): υ-=  3320, 2180 ; 1H 
NMR [CDCl3]: δ= 2.1(quintet, 4 H,2CH2), 2.5 (quintet, 
2H,CH2,), 2.9 (t, 4 H, -NCH2 ), 7.1-7.4 (m, 3H, Ar-H), 9.4(s, 
1H, =NH); Found (%): C, 55.56; H, 4.03; N, 20.12. Calc.for 
C16 H14 N5 S Cl (%): C, 55.89; H, 4.10; N, 20.37. 
5c:  yield 65%; M.p.:180oC; IR (FTIR): υ-= 3290, 2185; 1H 
NMR [CDCl3]: δ= 2.8 (quintet, 4 H, 2CH2), 3.6 (t, 4 H, -
NCH2), 7.3-7.7 (m, 3 H, Ar-H), 9.1 (s, 1H, =NH); Found (%): 
C, 54.31; H, 3.32; N, 21.12. Calc.for C15 H12 N5 S Cl (%): C, 
54.63; H, 3.67; N, 21.23. 
5d:  yield 55%; M.p.: 150oC; IR (FTIR): υ-=  3310, 3240, 
2215 ;  1H NMR[CDCl3]: δ=  2.9 (t, 4 H, -NCH2), 3.5 (t, 4 H, 
-NCH2), 7.2-7.7 (m, 3H, Ar-H), 8.8 (s, 1H, -NH), 9.3 (s, 1H, 
=NH) Found (%): C, 52.12; H, 3.40; N, 23.92. Calc.for C15 
H13 N6 S Cl (%): C, 52.25; H, 3.80; N, 24.37. 
6a:  yield 62%; M.p.: 180oC; IR (FTIR): υ-=3350, 2210, 
1260, 1040; 1H NMR [CDCl3]: δ= 7.2-7.9 (m, 8H, Ar-H), 9.5 
(s, 1H, =NH); Found (%): C, 57.52; H, 2.36; N, 15.58. 
Calc.for C17 H9 N4 SO Cl (%): C, 57.88; H, 2.57; N, 15.88. 
6b:  yield 60%; M.p.: 182oC; IR (FTIR): υ-= 3290, 2205, 
1240, 1010; 1H NMR [CDCl3]: δ=   7.4-8.0 (m, 7H, Ar-H), 
9.1 (s, 1H, =NH); Found (%): C, 52.60; H, 2.01; N, 14.27. 
Calc.for C17 H8 N4 SO Cl2 (%): C, 52.73; H, 2.08; N, 14.47. 
6c: yield 65%; M.p.: 210oC; IR (FTIR): υ-= 3310, 2195, 
1530, 1350, 1230, 1030; 1H NMR [CDCl3]: δ= 7.2-7.9 (m, 7 
H, Ar-H), 9.3 (s, 1H, =NH); Found (%): C, 51.05; H, 1.98; N, 
17.42. Calc.for C17 H8 N5 SO3 Cl (%): C, 51.33; H, 2.03; N, 
17.61. 
6d:  yield 59%; M.p.: 290oC; IR (FTIR): υ-= 3295, 2185, 
1260, 1050; 1H NMR [CDCl3]: δ= 2.1(s, 3 H, Ar-CH3), 7.2-
7.9 (m, 7 H, Ar-H), 9.2 (s, 1H, =NH); Found (%): C, 58.75; 
H, 3.00; N, 15.02. Calc.for C18 H11 N4 SO Cl (%): C, 58.94; 
H, 3.02; N, 15.27. 
7a:  yield 65%; M.p.:180oC; IR(FTIR): υ-= 3306, 2198, 1728 ; 
1H NMR[CDCl3]: δ= 1.2 (t, 3 H, CH3), 2.1 (s, 3 H, COCH3), 
2.6 (s, 1H, CH), 3.4 (q, 2 H, OCH2), 7.3-7.7 (m, 3H, Ar-H), 
9.4 (s, 1H, =NH);Ms, m/z (%):347 [M+2](33),345[ M ](100); 
Found (%): C, 52.22; H, 3.01; N, 14.25. Calc.for C17 H13 N4 
SO3 Cl (%): C, 52.50; H, 3.34; N, 14.41. 
7b:  yield 70%; M.p.: 184oC; IR(FTIR): υ-= 3320, 2180,1740 
; 1H NMR [CDCl3]: δ= 1.1 (t, 6 H, 2 CH3), 2.8 (s, 1H, CH), 
3.6 (q, 4 H, 2 CH2), 7.2-7.6 (m, 3H, Ar-H), 9.2 (s, 1H, =NH); 
Found (%): C, 54.27; H, 3.61; N, 14.65. Calc.for C19 H15 N4 
SO4 Cl (%): C, 54.54; H, 3.99; N, 14.91. 
7c:  yield 58%; M.p.: 170oC; IR(FTIR): υ-=3280, 2215, 1720; 
1H NMR[CDCl3]: δ=  1.3 (t, 3 H, CH3), 2.6 (s, 1H, CH), 3.0 
(q, 2H, OCH2), 7.1-7.5 (m, 3 H, Ar-H), 9.1 (s, 1H, =NH); 
Found (%): C, 51.03; H, 2.26; N, 18.25. Calc.for C16 H10 N5 
SO2 Cl (%): C, 51.13; H, 2.66; N, 18.64. 
7d:  yield 64%; M.p.: 190oC; IR (FTIR): υ-= 3310, 2115, 
1725; 1H NMR [CDCl3]: δ= 
 2.3 (s, 6 H, 2 COCH3), 3.1(s, 1H, CH), 7.2-7.6 (m, 3H, Ar-
H), 9.3 (s, 1H, =NH); Found (%): 
 C, 53.13; H, 3.06; N, 15.32. Calc.for C16 H11N4SO2 Cl (%): 
C, 53.56; H, 3.09; N, 15.61. 
 
Biological Activity 
Out of twenty, fourteen compounds were selected to in vitro 
preliminary screening for anticancer activity. The screening 
was carried by two stage process.   In first stage, all 
compounds were evaluated against the 60 cell lines at a single 
dose of 10 µM. The result of anticancer activity from the 
single dose screen is reported as a mean graph.  For second 
stage screening compounds 3, 4c, 4e which exhibit significant 
growth inhibition are selected by NCI for further anticancer 
activity evaluation against the 60 cell panel at five 
concentration levels. In graph, referred as ‘mean graph’, the 
mean of all cell lines results is considered as zero. This ‘mean 
graph’ is developed by plotting positive and negative values 
generated from a set of GI50  values .The positive and negative 
values are plotted along a vertical line that represents the 
mean  response of all the cell lines in the panel to the test 
agent. Positive values project to the right of the vertical line 
and represent celluar sensitivities to the test agent that exceed 
the mean. Negative values project to the left of the vertical 
line and represent cell line sensitivities to the test agent that 
are less than the average value. Compounds with cell lines 
appearing on positive side of mean graph exhibit high growth 
inhibition of cancer cells of that particular cancer. The results 
of in vitro anticancer screening are summarized in table 1. 
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RESULTS AND DISCUSSION:- 
              In the present work, we report one pot synthesis of 
new heterocyclic compounds, 8-Chloro3-cyano-4-imino-2-
methylthio-4H-pyrimido [2,1-b] [1,3] benzothiazole 3 and its 
2-substituted derivatives 4,5,6 and 7 .Compound 3 was 
prepared with 75% yield from the reaction of 
bis(methylthio)methylene malononitrile 2 with 2-amino-6-
chloro-benzothiazole 1 in the presence of N, N-
dimethylformamide and a catalytic amount of anhydrous 
potassium carbonate. The structure of this compound with mp 
230oC, was confirmed on the basis of elemental analysis, IR, 
1H NMR ,13C-NMR and mass spectral data. Spectral studies 
of compound 3 show that the compound is stable and does not 
exhibit any tautomerism. Scheme 1 represents a pathway for 
the formation of compound 3. 
                      Compound 3 possesses replaceable methylthio 
group at 2-position, activated by the ring nitrogen atom and 
electron withdrawing cyano group at 3- position. Hence, it is 
surmised that compound 3 would become best precursor for 
the synthesis of its 2-substitued derivatives. Accordingly  2-
substituted derivatives of compound 3 have been prepared by 
reacting compound 3 with selected N -, O- and C- 
nucleophiles like aryl /heteryl amines, substituted phenols and 
compounds containing active methylene group to get 
corresponding, 2-aryl/heteryl amines, aryloxy, ethyl 
acetoacetyl, diethyl malonyl, ethyl cyanoacetyl and acetyl 
acetonyl derivatives 4, 5, 6 and 7 .     
 According to this method , compound 3 independently ,on 
reaction with aniline ,4-nitro aniline ,4-methoxy aniline, 4- 
methyl aniline, 4-chloro aniline and diethyl amine in N,N-
dimethylformamide and a catalytic amount of anhydrous 
potassium carbonate afforded 8-chloro-3-cyano-4-imino-2-
(anilino/4-nitroanilino/ 4-methoxy anilino / 4-methyl anilino / 
4-chloroaniline/diethylamino)-4H-pyrimido[2,1-
b][1,3]benzothiazoles,4(a-f) respectively. Under similar 
experimental conditions, compound 3 was reacted 
independently with morpholine, piperidine, pyrrolidine and 
piperazine to obtain 8-chloro-3-cyano-4-imino-2-(morpholino 
/ piperidino / pyrrolidino / piperazino) -4H-pyrimido [2,1-b] 
[1,3] benzothiazoles, 5(a-d) respectively. 
                                  8-Chloro-3-cyano-4-imino-2-( phenoxy /  
4-chloro phenoxy / 4-nitro phenoxy / 4-methyl phenoxy ) 4H-
pyrimido [2,1-b] [1,3] benzothiazoles 6(a-d) were obtained by 
the condensation of compound 3 independently with phenol, 
4- chloro phenol, 4-nitro phenol and 4-methyl phenol in N,N-
dimethylformamide and catalytic amount of anhydrous 
potassium carbonate .Under similar experimental conditions, 
compound 3 was reacted independently with ethyl 
acetoacetate, diethyl malonate, ethyl cyanoacetate and acetyl 
acetone to obtain 8-chloro-3-cyano-4-imino-2-(ethyl 
acetoacetyl / diethyl malonyl / ethyl cyanoacetyl / acetyl 
acetonyl ) 4H-pyrimido[2,1-b] [1,3] benzothiazoles 7(a-d) 
respectively. Scheme 2 represents a pathway for the formation 
of compounds 4(a-f), 5(a-d), 6(a-d), and 7(a-d). 
 
 
 
N
S NCl
H
H
+
SCH
3
SCH
3
NN
S N
H
Cl
N
SCH
3
CNNC
 
S NCl
N
SCH
3
CN
NH
1
DMF
anhydrous K
2
CO
3
   Scheme - 1
3
2
 
 
 
 
 
 
 
 
JPRHC 
Research Article 
 
 
JPRHC                         Volume 2                                 Issue 3                                         273-278 
 
 
 
 
 
 
 
 
 
 
Table1. One dose mean graph data in vitro 60-cell drug screening
 a
 of activity of pyrimido  benzothiazole                
                                                                                                                                                                                                                                                                                                        
 
 
Sr.No 
(NSC No.) 
d
 
Comp 
No. 
 
       R 
                 GI50 (µ M ) in cell lines
b
 
HCC-
2998 
   HL-
60(TB) 
TK-10 MALME 
     3M           
  Du- 
  145 
 SF- 
  539 
Mean
c
 
GI50  
1(745689)2(
745676)3(74
5677) 
4(745678) 
5(745679) 
6(745680) 
7(745681) 
       8 
(745682) 
        9 
(745683) 
     10 
(745684) 
     11 
(745685) 
     
    12 
(745086) 
 
     13 
(745087) 
 
     14 
(745688) 
   3 
   4b 
   4c 
   4e 
   4f 
   6b 
    6c 
    5a 
 
  5b 
 
 5c 
 
 5d 
 
 
 7d 
 
 
  7c 
 
 
   7a 
 
-SCH3 
4-NHC6H4-NO2 
4-NHC6H4-CH3 
4-NHC6H4-Cl-
N(C2H5)2 
4-O-C6H4-Cl 
4-O-C6H4-NO2 
ON
 
N
 
N
 
NHN
 
 
COCH
3
COCH
3
CH
 
 
COOC
2
H
5
CN
CH
 
 
COOC
2
H
5
COCH
3
CH
 
18.01 
55 
23.63 
35.55 
 21.60 
31.84 
 39.10 
26.76 
 
 30.45 
 
56.15 
 
16.8 
 
 
4.90 
 
 
6.61 
 
 
48.12 
52.21 
26.84  
 47.14 
 45.07   
29.04 
11.07 
72.62  
11.78 
 
13.10 
 
33.84 
 
29.79 
 
 
 29.79 
 
 
7.20 
 
  
  
 
32.01 
15.08 
58.78 
45.65 
  36.15 
 77.19 
  44.96 
-28.47 
 64.91 
 
 58.46 
 
-8.93 
 
57.04 
 
 
105.60 
 
 
67.97 
 
 
  15.80 
-28.63 
1.44 
5.50 
13.58 
514.94 
13.90 
-88.98 
22.22 
 
5.75 
 
-1.95 
 
15.21 
 
 
12.60 
 
 
542.42 
 
 
  -30.81 
21.38 
18.30 
33.42 
25.90 
17.41 
16.84 
26.95 
23.08 
 
6.8 
 
10.67 
 
9.78 
 
 
14.95 
 
 
26.02 
 
 
21.38 
1.34 
17.41 
31.20 
31.02 
21.52 
49.48 
27.64 
13.08 
 
6.39 
 
112.4 
 
6.27 
 
 
 
 
12.94 
 
 
 
-3.60 
 
 
 
 
16.53 
68.76 
89.16 
71.86 
71.77 
85.45 
96.91 
78.37 
95.00 
 
96.85 
 
96.48 
 
100.96 
 
 
82.59 
 
 
102.90 
 
 
83.33 
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CONCLUSION 
 
In this paper, an easy and useful method to obtain biological 
active, 8-Chloro3-cyano-4-imino-2-methylthio-4H-pyrimido 
[2,1-b] [1,3] benzothiazole 3 and its 2-substituted derivatives 
4, 5,6 and 7 has been presented. The parent compound 3 
exhibits cytotoxic activity against HL-60(TB) cell line 
(Leukemia). 
       From the point of structure activity relationship, results 
obtained by first stage screening revealed that replacement of 
methylthio group at 2- position by 4-methoxy aniline 4c, 4-
chloro aniline 4e, 4- nitro phenoxy 6c and ethyl acetoacetyl 
7a were found to be cytotoxic against HL-60(TB) cell line 
(Leukemia). However amoungst these compounds, compound 
6c with 4- nitro phenoxy substituent was found to be most 
potent. 
        Compounds obtained by the replacement of methylthio 
group at 2- position by 4-nitro aniline 4b, diethyl amino 4f, 
morpholino 5a, piperidino 5b, piperazino 5d, ethyl cynoacetyl 
7c and acetyl acetonyl 7d groups revealed anticancer activity 
against TK-10 cell line(Renal cancer). However the presence 
of acetyl acetonyl group at 2- position 7d makes this 
compound most anticancer amoungst these compounds. 
 
                Compounds with substituents diethyl amino and 
ethyl cyno acetyl 4f, 7c respectively exhibited remarkable 
inhibitory effects against MALME-3M cell line (Melanoma). 
Compounds having 4-nitro aniline, pyrolidino, ethyl 
acetoacetynl substituent at 2- position 4b, 5c, 7a respectively 
showed antitumor activity against HCC-2998 cell line (Colon 
cancer) and 6b, 5c exhibited inhibitory cytotoxicity against  
SF-539 cell line (CNS). 
 All these compounds displayed cytyotoxicity response across 
cell lines, sensitive cell lines exhibit GI50 values <10
-8 M and 
insensitive cell lines >10-4 M. For second stage screening 
compounds 3, 4c and 4e exhibit significant growth inhibition 
are selected by NCI for further cytotoxicity by evaluation 
against 60 cell panels at five dose concentration levels.  
           Fused pyrimido benzothiazoles of the type 3, 4, 5, 6 
and 7 demonstrate cytotoxic properties justifying further 
investigation as the potential anticancer agents and may be 
used as a basis for the design of new non- toxic anticancer 
drugs.     
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